Elranatamab

Definition

A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

Also known as Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135, B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135, BCMA x CD3 Bispecific Antibody PF-06863135, BCMA-CD3 Bispecific Ab PF-06863135, ELRANATAMAB, Elranatamab-bcmm, Elrexfio, PF 06863135, PF-06863135, PF06863135, RN 613, RN-613, RN613 — per NCIT

Also identified as

• ATC L01FX32 per RXNORM
• NCIT NCIT:C146860 per NCIT
• SCTID 2054141000122109 per RXNORM
• UNII L0HR9A577V per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.